Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC22 in Chronic Hepatitis B
NCT04465890Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in Chronic Hepatitis B (CHB), sponsored by Ascletis Pharma Inc.. Started Jul 2020; status: completed.
02
Drugs
envafolimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04465890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465890.